Answers are grounded in this paper and cite their sources.
Stage IIIA-N2 Non-small cell lung cancer includes heterogenous group of patients with a poor 5-year survival ranging from 13% to 36% with surgery alone. Various randomized controlled trials established the role of multimodality treatment either including or excluding surgical resection. In a select group of non-bulky/ single station N2 disease, the better results have been achieved with induction chemotherapy or chemo-radiotherapy followed by surgery.
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: